N-of-1 trials of stimulants versus placebo and each other for Attention Deficit Hyperactivity Disorder in children

Submission date Recruitment status Prospectively registered 04/08/2007 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 16/08/2007 Completed [X] Results [] Individual participant data Last Edited Condition category 21/05/2019 Mental and Behavioural Disorders

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Geoff Mitchell

Contact details

Division of General Practice The University of Queensland Brisbane Australia 4006

Additional identifiers

Protocol serial number

ADHDAHMACGEN version 2; Also registered in Australian Clinical Trials Registry: ACTRN12605000507684

Study information

Scientific Title

N-of-1 trials of stimulants versus placebo and each other for Attention Deficit Hyperactivity Disorder in children

Acronym

ADHDIMET

Study objectives

- 1. N-of-1 trials will improve therapeutic decision making about Attention Deficit Hyperactivity Disorder (ADHD) medications, by educating the doctor and the patient in the use of N-of-1 trial methodology for objective individual patient decision making
- 2. N-of-1 trials will be able to evaluate individual patient responses to stimulants in terms of relief of ADHD symptoms, and immediate side-effect profile

Ethics approval required

Old ethics approval format

Ethics approval(s)

The University of Queensland Medical Research Ethics Committee and the Mater Misericordiae Hospital Medical Research Ethics Committee approved the study.

Study design

This N-of-1 trial is a randomised, double-blind, cross-over comparison of stimulants (methylphenidate or dexamphetamine) and placebo within an individual patient.

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Attention Deficit Hyperactivity Disorder

Interventions

- 1. Stimulant versus placebo
- 2. Stimulant versus stimulant

The stimulants being tested will be dexamphetamine and methylphenidate, compared to placebo and each other. The dose will be individualised by the child's doctor to the optimum dose without side effects, and will be taken orally at morning and lunchtime. There are two types of trials: treatments will take place in three day or one week periods; each pair of periods will be repeated three times (total of 3 and 6 weeks respectively). Follow-up will be for one year.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylphenidate, dexamphetamine

Primary outcome(s)

- 1. Conners' Teacher and Parent self reported revised short form
- 2. Conners-Wells Adolescent Rating Scales

Outcomes will be measured at baseline and at the end of each treatment period.

Key secondary outcome(s))

No secondary outcome measures

Completion date

01/05/2005

Eligibility

Key inclusion criteria

- 1. Any school age patient with a clinical diagnosis of ADHD of at least a month's duration, in the opinion of the attending medical practitioner, who is stabilised on treatment with Ritalin
- 2. Patient, parent and doctor would like to use the n-of-1 trial methodology to see if the patient is a responder to methylphenidate or dexamphetamine

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

Not Specified

Total final enrolment

86

Key exclusion criteria

- 1. Advanced arteriosclerosis
- 2. Symptomatic cardiovascular disease
- 3. Moderate to severe hypertension
- 4. Hyperthyroidism
- 5. Phaeochromocytoma
- 6. Glaucoma
- 7. Agitated states
- 8. Anxiety
- 9. Motor tics
- 10. Tourette syndrome
- 11. Monoamine Oxidase Inhibitors (MAOIs) (+/- 14 days)
- 12. Idiosyncratic reaction to sympathomimetic amines
- 13. History of drug abuse

Date of first enrolment

Date of final enrolment 01/05/2005

Locations

Countries of recruitment

Australia

Study participating centre
Division of General Practice
Brisbane
Australia
4006

Sponsor information

Organisation

The University of Queensland (Australia)

ROR

https://ror.org/00rqy9422

Funder(s)

Funder type

Government

Funder Name

General Practice Evaluation Program (GPEP) (Australia)

Funder Name

The Department of Health and Aged Care (Australia)

Funder Name

Queensland Medical Laboratory (Australia)

Funder Name

Mater Misericordiae Health Services (Brisbane, Australia)

Funder Name

The Royal Australian College of General Practitioners (Australia)

Funder Name

National Health and Medical Research Council (Australia) - medical postgraduate research scholarship (ref: 210364)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2006	21/05/2019	Yes	No